Sodium Picosulfate is a tri-aryl-methane group derivative stimulant laxative. After oral administration it is activated by the colonic bacteria and acts locally in the colon. The active form then stimulates the nerve endings of the intestinal wall and results in colonic peristalsis with promotion of accumulation of water and electrolytes in the colonic lumen. This results in stimulation of defecation, reduction of transit time and softening of the stool. Stimulation of the rectum causes increased motility and a feeling of rectal fullness. The rectal effect may help to restore the "call to stool".

Constipation of any etiology, relief from prolonged & recurrent constipation, bowel clearance before surgery, childbirth or radiological investigations.

For oral administration: The following dosages are recommended to be taken at night to produce evacuation the following morning. It is recommended to start with the lowest dose. The dose may be adjusted up to the maximum recommended dose to produce regular stools. The maximum recommended daily dose should not be exceeded: Adults and Children Over 10 Years of Age: 5-10 mg per day or 5-10 ml solution or 1 to 2 teaspoonful solution per day; Children aged 4-10 years: 2.5-5 mg tablet per day or 2.5-5 ml solution or ½ to 1 teaspoonful solution per day; Children under 4 years of age: 0.25 ml /kg body weight per day.

Illeum or intestinal obstruction, severe painful and/or feverish acute abdominal conditions (e.g. appendicitis) potentially associated with nausea and vomiting, acute inflammatory bowel diseases, severe dehydration, known hypersensitivity to Sodium Picosulfate or anyother component of the product.

Prolonged excessive use may lead to fluid and electrolyte imbalance and hypokalemia. Harmful for those suffering from alcoholism. To be taken into account in pregnant or breast-feeding women, children and high-risk groups such as patients with liver disease or epilepsy.

Hypersensitivity, dizziness, syncope, vasovagal response, gastrointestinal disorders, diarrhea, abdominal pain and abdominal cramps, nausea, vomiting.

Pregnancy: There are no reports of undesirable or damaging effects during pregnancy or to the fetus attributable to the use of this product. Use of the drug should be avoided during first trimester. Lactation Clinical data show that neither the active moiety of sodium Picosulfate (BHPM or bis-(phydroxyphenyl)-pyridyl-2-methane) nor its glucuronides are excreted into the milk of healthy lactating females.

The concomitant use of diuretics or adreno-corticosteroids may increase the risk of electrolyte imbalance if excessive doses are taken. Concurrent administration of antibiotics may reduce the laxative action of this product.

Laxatives when taken in chronic over dosage may cause chronic diarrhea, abdominal pain, hypokalemia, secondary hyperaldosteronism and renal calculi. Renal tubular damage, metabolic alkalosis and muscle weakness secondary to hypokalemia have also been described in association with chronic laxative abuse.

Store in a cool (below 30º C) and dry place. Keep out of the reach of the children.

Ezygo 10 Tablet: Each box contains 5 x 10 tablets in blister pack. Ezygo Oral Solution: Each bottle containing 100 ml Oral Solution.